Technical Analysis for BHVN - Biohaven Pharmaceutical Holding Company Ltd.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical BHVN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jun 22 | 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% |
| Jun 22 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Jun 22 | NR7 | Range Contraction | 0.00% |
| Jun 22 | Multiple of Ten Bullish | Other | 0.00% |
| Jun 22 | Inside Day | Range Contraction | 0.00% |
| Jun 21 | Upper Bollinger Band Walk | Strength | 0.57% |
| Jun 21 | Multiple of Ten Bullish | Other | 0.57% |
| Jun 20 | Bearish Engulfing | Bearish | -2.32% |
| Jun 20 | Slingshot Bullish | Bullish Swing Setup | -2.32% |
| Jun 20 | Upper Bollinger Band Walk | Strength | -2.32% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-06-15
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more BHVN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 44.28 |
| 52 Week Low | 16.5 |
| Average Volume | 432,897 |
| 200-Day Moving Average | 30.1767 |
| 50-Day Moving Average | 32.1978 |
| 20-Day Moving Average | 37.412 |
| 10-Day Moving Average | 39.853 |
| Average True Range | 1.8423 |
| ADX | 38.21 |
| +DI | 29.26 |
| -DI | 15.74 |
| Chandelier Exit (Long, 3 ATRs ) | 38.7531 |
| Chandelier Exit (Short, 3 ATRs ) | 38.5369 |
| Upper Bollinger Band | 43.0098 |
| Lower Bollinger Band | 31.8142 |
| Percent B (%b) | 0.77 |
| BandWidth | 29.925158 |
| MACD Line | 2.6362 |
| MACD Signal Line | 2.502 |
| MACD Histogram | 0.1342 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.45 Billion |
| Num Shares | 35.8 Million |
| EPS | -7.54 |
| Price-to-Earnings (P/E) Ratio | -5.36 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 5.62 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 42.63 | ||||
| Resistance 3 (R3) | 42.57 | 41.75 | 42.26 | ||
| Resistance 2 (R2) | 41.75 | 41.18 | 41.79 | 42.13 | |
| Resistance 1 (R1) | 41.07 | 40.83 | 41.41 | 41.13 | 42.00 |
| Pivot Point | 40.25 | 40.25 | 40.43 | 40.29 | 40.25 |
| Support 1 (S1) | 39.57 | 39.68 | 39.91 | 39.63 | 38.76 |
| Support 2 (S2) | 38.75 | 39.33 | 38.79 | 38.63 | |
| Support 3 (S3) | 38.07 | 38.75 | 38.51 | ||
| Support 4 (S4) | 38.13 |
